Triamcinolone + nystatin + neomycin + gramicidin


Generic Medicine Info
Contraindications
Tuberculous, viral lesions of the skin (e.g. herpes simplex and varicella); fungal lesions not susceptible to nystatin, facial rosacea, acne vulgaris or perioral dermatitis. Not to be applied to the external auditory canal in patients with perforated tympanic membranes. Do not use on extensive areas to reduce risk of systemic absorption and neomycin-induced ototoxicity. Not recommended for <1 yr.
Special Precautions
Patients with established hearing loss. Avoid occlusive dressing and prolonged or recurrent use. Avoid contact with eyes or mucous membranes. If there is no clinical improvement after 7 days, discontinue use as the infection may be masked by the steroid. Limit use to 5 days if used on the face or on children ≥1 yr. Use with caution and sparingly on inflamed or damaged skin (e.g extensive burns, trophic ulceration). Pregnancy.
Adverse Reactions
Prolonged use may cause sensitivity reactions, impaired wound healing, thinning of skin, striae, telangiectasia, hirsutism, hypothalamic-pituitary-adrenal axis suppression, Cushing's syndrome. Ototoxicity and nephrotoxicity.
ATC Classification
S01BA05 - triamcinolone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
A01AB08 - neomycin ; Belongs to the class of local antiinfective and antiseptic preparations. Used in the treatment of diseases of the mouth.
S03AA01 - neomycin ; Belongs to the class of antiinfectives used in ophthalmologic and otologic preparations.
R02AB01 - neomycin ; Belongs to the class of antibiotics used in throat preparations.
G01AA01 - nystatin ; Belongs to the class of antibiotics. Used in the treatment of gynecological infections.
R02AB30 - gramicidin ; Belongs to the class of antibiotics used in throat preparations.
J01GB05 - neomycin ; Belongs to the class of other aminoglycosides. Used in the systemic treatment of infections.
A07AA01 - neomycin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
B05CA09 - neomycin ; Belongs to the class of antiinfectives used as irrigating solutions.
R03BA06 - triamcinolone ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.
D06AX04 - neomycin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
D01AA01 - nystatin ; Belongs to the class of antibiotics. Used in the topical treatment of fungal infection.
H02AB08 - triamcinolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
S02AA07 - neomycin ; Belongs to the class of antiinfectives used in the treatment of ear infections.
S01AA03 - neomycin ; Belongs to the class of antibiotics. Used in the treatment of eye infections.
R01AD11 - triamcinolone ; Belongs to the class of topical corticosteroids used for prophylaxis and treatment of allergic rhinitis.
D07XB02 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
C05AA12 - triamcinolone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
A07AA02 - nystatin ; Belongs to the class of antibiotics. Used in the treatment of intestinal infections.
A01AC01 - triamcinolone ; Belongs to the class of local corticosteroid preparations. Used in the treatment of diseases of the mouth.
D07AB09 - triamcinolone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
Disclaimer: This information is independently developed by CIMS based on triamcinolone + nystatin + neomycin + gramicidin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in